Compare Norfolk Southern Corporation (NSC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs TG Therapeutics Inc — how do they compare? Norfolk Southern Corporation trades at $317.62 (market cap $71.20B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Norfolk Southern Corporation is far larger — about 8.7× TG Therapeutics Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and TG Therapeutics Inc for 16 Days on average.
| NSC | TGTX | |
|---|---|---|
Market Cap | $71.20B | $8.16B |
Volume | 555,248 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $352.98 | $59.06 |
52-Week Low | $278.19 | $26.94 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $86.75B | $8.37B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $317.79, up 1.47% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected on October 22, 2026. Fundamentals show strong profitability with a 21.02% net income margin and 16.97% ROE, though revenue growth is modest. The proposed merger with Union Pacific is a key development, gaining regulatory and customer support.
The outlook is positive, supported by earnings momentum and merger potential, offering upside to the $361.86 consensus price target. Risks include merger approval uncertainty, fuel cost pressures noted in September 2026, and a high P/E ratio of 27.05. Institutional interest remains strong, with recent investments from firms like Bank of America.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
